TY  - GEN
AU  - García-Alfonso, Pilar
AU  - Muñoz, Andrés
AU  - Jiménez-Castro, Jerónimo
AU  - Jiménez-Fonseca, Paula
AU  - Pericay, Carles
AU  - Longo-Muñoz, Federico
AU  - Reyna-Fortes, Carmen
AU  - Argilés-Martínez, Guillem
AU  - González-Astorga, Beatriz
AU  - Gómez-Reina, María José
AU  - Ruiz-Casado, Ana
AU  - Rodríguez-Salas, Nuria
AU  - López-López, Rafael
AU  - Carmona-Bayonas, Alberto
AU  - Conde-Herrero, Verónica
AU  - Aranda, Enrique
PY  - 2021
DO  - 10.3390/cancers13184514
UR  - http://hdl.handle.net/20.500.12105/18457
AB  - Trifluridine/tipiracil is currently approved for metastatic colorectal cancer (mCRC) refractory to available therapies. However, there is no consensus on factors that predict treatment outcomes in daily practice. We assessed the early clinical...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - Biomarkers
KW  - Chemotherapy
KW  - Colorectal cancer
KW  - Combination therapy
KW  - Real-life
KW  - Trifluridine/tipiracil
KW  - Biomarcadores
KW  - Quimioterapia
KW  - Neoplasias colorrectales
KW  - Quimioterapia combinada
KW  - Trifluridina
KW  - Humans
KW  - Trifluridine
KW  - Alkaline Phosphatase
KW  - Neutrophils
KW  - Retrospective Studies
KW  - Spain
KW  - Tumor Burden
KW  - Colorectal Neoplasms
KW  - Neutropenia
KW  - Treatment Outcome
KW  - Disease Progression
KW  - Regression Analysis
KW  - Thrombocytopenia
KW  - Digestive System Neoplasms
KW  - Lymphocytes
KW  - Anemia
TI  - Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
TY  - research article
ER  -